138 related articles for article (PubMed ID: 20952484)
1. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase.
Matsumoto K; Okamoto K; Ashizawa N; Nishino T
J Pharmacol Exp Ther; 2011 Jan; 336(1):95-103. PubMed ID: 20952484
[TBL] [Abstract][Full Text] [Related]
2. Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor.
Omura K; Nakazawa T; Sato T; Iwanaga T; Nagata O
Drug Metab Dispos; 2007 Dec; 35(12):2143-8. PubMed ID: 17761779
[TBL] [Abstract][Full Text] [Related]
3. Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides.
Nakazawa T; Miyata K; Omura K; Iwanaga T; Nagata O
Drug Metab Dispos; 2006 Nov; 34(11):1880-6. PubMed ID: 16914512
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].
Sato T; Ashizawa N; Matsumoto K; Iwanaga T; Nakamura H; Inoue T; Nagata O
Bioorg Med Chem Lett; 2009 Nov; 19(21):6225-9. PubMed ID: 19783139
[TBL] [Abstract][Full Text] [Related]
5. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion.
Fukunari A; Okamoto K; Nishino T; Eger BT; Pai EF; Kamezawa M; Yamada I; Kato N
J Pharmacol Exp Ther; 2004 Nov; 311(2):519-28. PubMed ID: 15190124
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Shimo T; Ashizawa N; Matsumoto K; Nakazawa T; Nagata O
Toxicol Sci; 2005 Sep; 87(1):267-76. PubMed ID: 15933230
[TBL] [Abstract][Full Text] [Related]
7. Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
Shimo T; Ashizawa N; Moto M; Iwanaga T; Nagata O
Arch Toxicol; 2011 May; 85(5):505-12. PubMed ID: 20936465
[TBL] [Abstract][Full Text] [Related]
8. FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeys.
Shimo T; Ashizawa N; Moto M; Matsumoto K; Iwanaga T; Nagata O
Toxicol Pathol; 2009 Jun; 37(4):438-45. PubMed ID: 19336671
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Okamoto K; Nishino T
J Nippon Med Sch; 2008 Feb; 75(1):2-3. PubMed ID: 18360072
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol.
Okamoto K; Eger BT; Nishino T; Pai EF; Nishino T
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):888-93. PubMed ID: 18600558
[TBL] [Abstract][Full Text] [Related]
11. Strain differences in the responsiveness between Sprague-Dawley and Fischer rats to nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
Ashizawa N; Shimo T; Matsumoto K; Oba K; Nakazawa T; Nagata O
Toxicol Appl Pharmacol; 2006 Dec; 217(3):260-5. PubMed ID: 17084874
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors.
Sato T; Ashizawa N; Iwanaga T; Nakamura H; Matsumoto K; Inoue T; Nagata O
Bioorg Med Chem Lett; 2009 Jan; 19(1):184-7. PubMed ID: 19027292
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical and kinetic properties of purified sheep's milk xanthine oxidoreductase.
Benboubetra M; Baghiani A; Atmani D; Harrison R
J Dairy Sci; 2004 Jun; 87(6):1580-4. PubMed ID: 15453470
[TBL] [Abstract][Full Text] [Related]
14. Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Ashizawa N; Shimo T; Matsumoto K; Taniguchi T; Moto M; Nagata O
Drug Chem Toxicol; 2011 Apr; 34(2):151-61. PubMed ID: 21105859
[TBL] [Abstract][Full Text] [Related]
15. 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors.
Cai J; Baugh M; Black D; Long C; Jonathan Bennett D; Dempster M; Fradera X; Gillespie J; Andrews F; Boucharens S; Bruin J; Cameron KS; Cumming I; Hamilton W; Jones PS; Kaptein A; Kinghorn E; Maidment M; Martin I; Mitchell A; Rankovic Z; Robinson J; Scullion P; Uitdehaag JC; Vink P; Westwood P; van Zeeland M; van Berkom L; Bastiani M; Meulemans T
Bioorg Med Chem Lett; 2010 Aug; 20(15):4350-4. PubMed ID: 20598883
[TBL] [Abstract][Full Text] [Related]
16. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors.
Li J; Wu F; Liu X; Zou Y; Chen H; Li Z; Zhang L
Eur J Med Chem; 2017 Nov; 140():20-30. PubMed ID: 28918097
[TBL] [Abstract][Full Text] [Related]
18. Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor.
Taniguchi T; Ashizawa N; Matsumoto K; Iwanaga T; Saitoh K
J Pharm Pharmacol; 2016 Jan; 68(1):76-83. PubMed ID: 26589240
[TBL] [Abstract][Full Text] [Related]
19. Nitrite-derived nitric oxide by xanthine oxidoreductase protects the liver against ischemia-reperfusion injury.
Lu P; Liu F; Yao Z; Wang CY; Chen DD; Tian Y; Zhang JH; Wu YH
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):350-5. PubMed ID: 16109514
[TBL] [Abstract][Full Text] [Related]
20. Goats' milk xanthine oxidoreductase is grossly deficient in molybdenum.
Atmani D; Benboubetra M; Harrison R
J Dairy Res; 2004 Feb; 71(1):7-13. PubMed ID: 15068060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
